Obalon is an engineering-driven medical technology company with a singular focus on innovative, high-quality gastric balloon technology. Located in San Diego, California, the technical team at Obalon has a long history of working closely with leading clinicians to develop innovative medical products that revolutionize treatment of chronic disease. As a company, we believe in the fundamental value of imagination and invention, combined with rigorous testing and analysis, to ensure the highest levels of safety and performance. The result is a user-focused approach that deploys the power of advanced technological thinking to support clinical treatment objectives.
Type
Public
HQ
Carlsbad, US
Founded
2008
Size (employees)
91 (est)
Website
obalon.com
Obalon Therapeutics was founded in 2008 and is headquartered in Carlsbad, US
Report incorrect company information

Key People/Management at Obalon Therapeutics

Mark Brister

Mark Brister

VP of R&D
Nooshin Hussainy

Nooshin Hussainy

Financial Controller
Show more

Obalon Therapeutics Office Locations

Obalon Therapeutics has an office in Carlsbad
Carlsbad, US (HQ)
f 5421 Avenida Encinas
Show all (1)
Report incorrect company information

Obalon Therapeutics Financials and Metrics

Obalon Therapeutics Revenue

Obalon Therapeutics's revenue was reported to be $9.91 m in FY, 2017
USD

Revenue (Q1, 2018)

1.3 m

Gross profit (Q1, 2018)

577 k

Gross profit margin (Q1, 2018), %

42.9%

Net income (Q1, 2018)

(12.1 m)

EBIT (Q1, 2018)

(12.1 m)

Market capitalization (18-Jul-2018)

34.6 m

Closing share price (18-Jul-2018)

2

Cash (31-Mar-2018)

33.5 m
Obalon Therapeutics's current market capitalization is $34.6 m.
Annual
USDFY, 2016FY, 2017

Revenue

9.9 m

Cost of goods sold

2.8 m4.8 m

Gross profit

(2.8 m)5.1 m

Gross profit Margin, %

51%
Quarterly
USDQ3, 2016Q1, 2017Q2, 2017Q1, 2018

Revenue

773 k1.5 m2 m1.3 m

Cost of goods sold

644 k823 k990 k769 k

Gross profit

129 k649 k973 k577 k

Gross profit Margin, %

17%44%50%43%
Annual
USDFY, 2016FY, 2017

Cash

73 m21.1 m

Accounts Receivable

2.9 m4.2 m

Inventories

827 k1.4 m

Current Assets

78.1 m51.8 m
Quarterly
USDQ3, 2016Q1, 2017Q2, 2017Q1, 2018

Cash

2.3 m41.7 m5.8 m33.5 m

Accounts Receivable

1 m1.8 m

Inventories

438 k928 k747 k1.9 m

Current Assets

18 m69.7 m63.9 m39.1 m
Annual
USDFY, 2016FY, 2017

Net Income

(20.5 m)(34.8 m)

Depreciation and Amortization

192 k330 k

Inventories

(464 k)(591 k)

Accounts Payable

46 k624 k
Quarterly
USDQ3, 2016Q1, 2017Q1, 2018

Net Income

(5.3 m)(7.7 m)(12.1 m)

Depreciation and Amortization

129 k

Inventories

438 k928 k(449 k)

Accounts Payable

1.1 m823 k1.1 m
USDY, 2018

Financial Leverage

1.7 x
Show all financial metrics
Report incorrect company information

Obalon Therapeutics News and Updates

Report incorrect company information

Obalon Therapeutics Company Life and Culture

Report incorrect company information